PRNewswire
Continuity Biosciences beruft Vicky Papoutsis in den VorstandFührungskraft für Geschäftsentwicklung und Unternehmensstrategie wird Vorstandsmitglied, während das Unternehmen seine klinischen Programme und Partnerschaftsaktivitäten vorantreibt BRADENTON, Florida, 31. Juli… Read more »
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company… Read more »
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026SAN DIEGO, July 30, 2026 /PRNewswire/ — Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results… Read more »
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favoring the Selinexor… Read more »
Castle Biosciences Reports Second Quarter 2026 ResultsDelivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased… Read more »- PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026… Read more »
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDENDTHOUSAND OAKS, Calif., July 30, 2026 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52… Read more »
GRAIL to Present at the Canaccord Genuity 46th Annual Growth ConferenceMENLO PARK, Calif., July 30, 2026 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect… Read more »
Neurocrine Biosciences Reports Second-Quarter 2026 Financial ResultsTotal Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to… Read more »
Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing TransactionNEW YORK, July 30, 2026 /PRNewswire/ — Global law firm Greenberg Traurig, LLP advised Ashlins Ocular Pharmaceuticals, Inc. (Ashlins), a… Read more »
Proteotype Launches €3 Million European Study to Advance Multi-Cancer Detection and Evaluate Home Blood CollectionThe INNOVATOR study will expand validation of Enlighten® across 12 cancers and assess whether capillary blood collection could enable a… Read more »
Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AMLClinicians often reduce the duration of venetoclax because of side effects, but study finds 14-day schedule fell short in older… Read more »
Proteotype Launches €3 Million European Study to Advance Multi-Cancer Detection and Evaluate Home Blood CollectionThe INNOVATOR study will expand validation of Enlighten® across 12 cancers and assess whether capillary blood collection could enable a… Read more »
POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALLRepatha ist der einzige PCSK9-Hemmer, der in einer klinischen Phase-3-Studie nachweislich das Risiko eines ersten Herzinfarkts und Schlaganfalls signifikant senkt… Read more »
AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVCRepatha est le seul inhibiteur de PCSK9 dont l’efficacité a été démontrée pour réduire de manière significative le risque de… Read more »
Lupin Announces U.S. FDA Approval and Launch of Sugammadex InjectionMUMBAI, India and NAPLES, Fla., July 30, 2026 /PRNewswire/ — Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN)… Read more »
Expert insights on diabetes care, space diagnostics, Alzheimer's and Down syndrome linkages, and advances in cancer screening draw nearly 17,000 attendees to ADLM 2026ANAHEIM, Calif., July 30, 2026 /PRNewswire/ — The Association for Diagnostics & Laboratory Medicine (ADLM) welcomed thousands of the greatest… Read more »
National Kidney Registry & National Liver Registry Hosts Webinar for Transplant Centers to Prepare for New OPTN Serology Testing PolicyGREENWICH, Conn., July 30, 2026 /PRNewswire/ — More than 200 representatives of the National Kidney Registry and National Liver Registry… Read more »- Peer-Reviewed Study Validates First Blood Test for Early-Stage Breast Cancer DetectionPublished study reports >92% sensitivity and specificity, outperforming current standards for supplemental screening SAINT PAUL, Minn., July 30, 2026 /PRNewswire/… Read more »
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsightThe inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn’s disease and ulcerative colitis,… Read more »